Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000960848 | SCV001107874 | benign | not provided | 2024-01-12 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003935933 | SCV004751749 | benign | FAT1-related condition | 2022-11-30 | criteria provided, single submitter | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Department of Pathology and Laboratory Medicine, |
RCV000960848 | SCV001549082 | likely benign | not provided | no assertion criteria provided | clinical testing | The FAT1 p.Glu1292Lys variant was not identified in the literature nor was it identified in ClinVar, Cosmic, or LOVD 3.0. The variant was identified in dbSNP (ID: rs184443677) and in control databases in 226 of 280594 chromosomes at a frequency of 0.000805 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: East Asian in 203 of 19530 chromosomes (freq: 0.01039), Other in 6 of 7138 chromosomes (freq: 0.000841), Latino in 7 of 35370 chromosomes (freq: 0.000198), South Asian in 6 of 30602 chromosomes (freq: 0.000196), African in 3 of 24176 chromosomes (freq: 0.000124) and European (non-Finnish) in 1 of 128406 chromosomes (freq: 0.000008), but was not observed in the Ashkenazi Jewish or European (Finnish) populations. The p.Glu1292 residue is conserved across mammals and other organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. |